Skip to content
Menu
Home
about AesMed
AesMed Story
AGF39
3rd Evolution in the History of Alopecia Treatment: AGF39 Cytokines Therapy for Alopecia
2025-04-22
The journey to effectively treating hair loss has seen significant advancements, with the ...
Read More
Previous
1
2
3
Latest Posts
Beyond the Device: How SCALPORIN™ R1 Fits into AGF39 Protocols and the CytoMesopecia Concept
Inside SCALPORIN™ R1: AesMed’s Professional Electroporation Scalp Device for Precision Delivery
Why Delivery Matters in Scalp Care: Electroporation, Active Solutions, and the Logic Behind Professional Treatment
AesMed Successfully Concludes KIMES 2026 Participation
From Conference Posters to Credibility: How SGF57 Built Trust – Series Part 3
The Clinical Study Behind the Original SGF57 Formula – Series Part 2
SGF57: The Original Blueprint Behind AGF39 – Series Part 1
AGF39: Clinical Experience, Real-World Data, and Global Adoption- part 4
CytoMesopecia – Cytokines Mesotherapy for Alopecia- part 3
Why Korea Leads Cytokines Mesotherapy for Hair Regrowth- part 2
Search for:
